Meglumine antimoniate
Meglumine antimoniate
|
Systematic (IUPAC) name |
---|
Hydroxy-dioxostiborane; (2R,3R,4R,5S)-6-methylaminohexane-1,2,3,4,5-pentol |
Clinical data |
---|
AHFS/Drugs.com |
Micromedex Detailed Consumer Information |
---|
Identifiers |
---|
|
133-51-7 N |
---|
|
P01CB01 QP51AB01 |
---|
PubChem |
CID 64953 |
---|
ChemSpider |
58479 Y |
---|
ChEMBL |
CHEMBL239129 Y |
---|
NIAID ChemDB |
008733 |
---|
Chemical data |
---|
Formula |
Variable |
---|
|
Variable |
---|
SMILES
- O=[Sb](=O)O.O[C@@H]([C@@H](O)[C@H](O)[C@@H](O)CNC)CO
|
InChI=1S/C7H17NO5.H2O.2O.Sb/c1-8-2-4(10)6(12)7(13)5(11)3-9;;;;/h4-13H,2-3H2,1H3;1H2;;;/q;;;;+1/p-1/t4-,5+,6+,7+;;;;/m0..../s1
Y
Key:XOGYVDXPYVPAAQ-SESJOKTNSA-M
Y
|
N (what is this?) (verify) |
---|
Meglumine antimoniate (or meglumine antimonate) is a medicine used for treating leishmaniasis.[1] It is manufactured by Aventis[2] and sold as Glucantime in France, and Glucantim in Italy. It belongs to a group of compounds known as the pentavalent antimonials. It is administered by intramuscular injection.
See also
References
- ↑ Soto, J.; Fuya, P.; Herrera, R.; Berman, J. (1998). "Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: Controlled study". Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 26 (1): 56–58. doi:10.1086/516267. PMID 9455509.
- ↑ Aventis press release, 15 April 2005. (German)
|
---|
| Discicristata | |
---|
| Trichozoa | |
---|
| |
---|
| Description |
- Alveolata
- Amoebozoa
- Excavata
- Protist
|
---|
| Disease |
- Amoebozoa
- Chromalveolate
- Excavata
|
---|
| Treatment |
- Drugs
- amoeboa
- chromalveolate
- excavata
|
---|
|
|